Get started
Author

Joachim Stangier

Idarucizumab for Dabigatran Reversal
2015 · Charles V. Pollack, Paul A. Reilly, et al. · New England Journal of Medicine · 1,563
Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity
2010 · Joachim Stangier, Sebastian Haertter, et al. · Thrombosis and Haemostasis · 1,380
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis
2017 · Charles V. Pollack, Paul A. Reilly, et al. · New England Journal of Medicine · 1,172
PDF
The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects
2007 · Joachim Stangier, Karin Rathgen, et al. · British Journal of Clinical Pharmacology · 887
Influence of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Dabigatran Etexilate
2010 · Joachim Stangier, Karin Rathgen, et al. · Clinical Pharmacokinetics · 720
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
2007 · Stefan Blech, Thomas Ebner, et al. · Drug Metabolism and Disposition · 695
Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran Etexilate
2008 · Joachim Stangier · Clinical Pharmacokinetics · 659
Pharmacokinetics and Pharmacodynamics of the Direct Oral Thrombin Inhibitor Dabigatran in Healthy Elderly Subjects
2008 · Joachim Stangier, Hildegard Stähle, et al. · Clinical Pharmacokinetics · 427
Dabigatran With or Without Concomitant Aspirin Compared With Warfarin Alone in Patients With Nonvalvular Atrial Fibrillation (PETRO Study)
2007 · Michael D. Ezekowitz, Paul A. Reilly, et al. · The American Journal of Cardiology · 420
A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial
2004 · B.I. ERIKSSON, O.E. DAHL, et al. · Journal of Thrombosis and Haemostasis · 414
Pharmacology, Pharmacokinetics, and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor
2009 · Joachim Stangier, Andreas Clemens · Clinical and Applied Thrombosis/Hemostasis · 340
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial
2015 · Stephan Glund, Joachim Stangier, et al. · The Lancet · 324
Pharmacokinetic Profile of the Oral Direct Thrombin Inhibitor Dabigatran Etexilate in Healthy Volunteers and Patients Undergoing Total Hip Replacement
2005 · Joachim Stangier, Bengt I. Eriksson, et al. · The Journal of Clinical Pharmacology · 295
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
2012 · Joachim Stangier, Martin Feuring · Blood Coagulation & Fibrinolysis · 267
A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist
2000 · Wolfgang Wienen, Michael Entzeroth, et al. · Cardiovascular Drug Reviews · 263
A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran
2015 · Viktoria Moschetti, Stephen Norris, et al. · Thrombosis and Haemostasis · 247
Unusual cardioactive peptide (CCAP) from pericardial organs of the shore crab Carcinus maenas
1987 · J. Stangier, C. Hilbich, et al. · Proceedings of the National Academy of Sciences · 227
Dabigatran: An Oral Novel Potent Reversible Nonpeptide Inhibitor of Thrombin
2010 · Wolfgang G. Eisert, Norbert Hauel, et al. · Arteriosclerosis Thrombosis and Vascular Biology · 217
Pharmacokinetics of Orally and Intravenously Administered Telmisartan in Healthy Young and Elderly Volunteers and in Hypertensive Patients
2000 · J Stangier, CAPF Su, et al. · Journal of International Medical Research · 212
Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I
2004 · B.I. Eriksson, O.E. Dahl, et al. · Journal of Thrombosis and Haemostasis · 202
PDF
Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment
2008 · Joachim Stangier, Hildegard Stähle, et al. · The Journal of Clinical Pharmacology · 178
Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
2015 · Paul A. Reilly, Richard Bernstein, et al. · Thrombosis and Haemostasis · 155
Absorption, Metabolism, and Excretion of Intravenously and Orally Administered [14C]Telmisartan in Healthy Volunteers
2000 · Joachim Stangier, Jochen Schmid, et al. · The Journal of Clinical Pharmacology · 149
AT1 Receptor Antagonist Telmisartan Administered Peripherally Inhibits Central Responses to Angiotensin II in Conscious Rats
2001 · P. Gohlke, S. Weiss, et al. · Journal of Pharmacology and Experimental Therapeutics · 130
Effects of the direct thrombin inhibitor dabigatran on ex vivo coagulation time in orthopaedic surgery patients: a population model analysis
2006 · Karl‐Heinz Liesenfeld, Hans G. Schäfer, et al. · British Journal of Clinical Pharmacology · 118
PDF
Works count: 75
Citation count: 13,210
H-index: 40
I10-index: 60
Year
Topic
Type